Historical survival for patients 18-45 years with ALL is approximately 40 %.

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission.

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Hodgkin Lymphoma typically affects young men and women in their 30s.

A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER! We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is…

Copenhagen, June 9 2016. At the 21st Congress of the European Hematology Association (EHA) in Copenhagen, in total thirteen hematology researchers will be awarded for their work. Research is the engine that drives improvements in patient care which is why EHA is keen in investing in Awards and Grants to stimulate and support hematology research.

The Hague, January 27, 2016 In the February 2016 issue of Haematologica, critical research of blood and blood-forming organs in Europe is given a boost. The European Hematology Association Roadmap for European Hematology Research: A Consensus Document summarizes the current status of basic, translational and clinical hematology research and identifies areas of unmet scientific and medical need in Europe. It provides guidance for European and national policy makers, funding agencies, charities, research institutes and researchers when they make decisions on initiating or funding research and developing research programs.

Vienna, June 12, 2015 – Promising results from an early phase trial combining the anti-bcl-2 drug Venetoclax with Rituximab to eliminate CLL are presented by Dr Andrew Roberts.

Vienna, June 12, 2015 –Dr Guryanova will present a new mechanism for chemoresistance in AML based on acquired DNA mutations.

Vienna, June 12, 2015 –Dr Marneth will discuss the findings of eight new genetic variants in GFI1B that have been discovered in patients with bleeding and platelet disorders and consequences for new therapeutic targets.

Vienna, June 12, 2015 –Dr Mesa will present new data from the phase 3 PERSIST-1 study on improving disease symptoms and quality of life for patients with myelofibrosis.